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Abstract  21 
This was a screening study that aimed to determine the presence of nephrotoxic 22 
mycotoxins in urine samples from patients with chronic kidney disease of 23 
uncertain etiology (CKDue) in the North Central Province of Sri Lanka. The 24 
percentage detection of aflatoxins (AFLs), ochratoxins (OTs) and fumonisins in 25 
31 patients were 61.29%, 93.5% and 19.4%, respectively. Geometric means of 26 
urinary AFLs and OTs were 30.93 ng/g Cr (creatinine) and 34.62 ng/g Cr in 27 
CKDue stage 1–2 patients and 84.12 ng/g Cr and 63.52 ng/g Cr in unaffected 28 
relatives of patients. In CKDue stage 3–5 patients, geometric means of urinary 29 
AFLs and OTs were 10.40 and 17.08 ng/g Cr, respectively. Non-affected relatives 30 
of patients (n=6) had comparable levels of these mycotoxins, but healthy Japanese 31 
individuals (n=4) had lower levels than in Sri Lanka. The higher detection rate of 32 
urinary OTs in Sri Lankans indicates that exposure is common in the region. 33 
Keywords chronic kidney disease of uncertain etiology, Sri Lanka, urine sample, 34 




High prevalence of chronic kidney disease of uncertain etiology (CKDue) in the 37 
North Central Province of Sri Lanka has been reported. The disease 38 
predominantly affects male farming communities. Several hypotheses have been 39 
made to explain the causal associations between the high prevalence of the disease 40 
in the region and existing environmental factors (Chandrajith et al. 2010; 41 
Illeperuma et al. 2009).  42 
Mycotoxins, such as aflatoxins (AFLs) (Glahn et al. 1994), ochratoxins 43 
(OTs) (Sauvant et al. 2005) and fumonisins (FBs) (Badria et al. 1996) are dietary 44 
contaminants that are known to possess nephrotoxicity. Detection of OT 45 
associated with the incidence of endemic nephropathy in some regions has been 46 
reported (Castegnaro et al. 2005; Domijan et al. 2009). A recent study by 47 
Wanigasuriya et al. (2008) has reported that the concentration of OT A in selected 48 
food items in the study region was low. Food analysis, in some instances, might 49 
not be sufficient to establish a relationship with occurrence of diseases because 50 
heterogeneity of toxin distribution over time, and even within a particular food 51 
product, casts doubt on the feasibility of sampling plans (Parson et al. 2007). In an 52 
attempt to overcome this problem and to validate the actual exposure, we screened 53 
urinary excretion levels of AFL, OTs and FBs in patients and their relatives living 54 
in a CKD endemic community.  55 
 56 
Materials and Methods 57 
Ethical approval for this study was obtained from the Ethical Committee of Kyoto 58 
University, Japan and the Ethical Review Committees of the Faculty of Medicine, 59 
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University of Peradeniya, Sri Lanka. The urine samples were originally collected 60 
at Medawachchiya and Girandrukotte, Sri Lanka in August 2009 (106 patients and 61 
87 unaffected relatives of CKDue patients) and stored at –30°C in the Kyoto 62 
University Human Specimen Bank (Koizumi et al. 2009). A total of 41 urine 63 
samples, 31 from stage 1–5 CKDue patients, six from unaffected relatives, and 64 
four from healthy Japanese individuals as controls, were randomly selected from 65 
each stratum. Definition of CKD and further classification of the stages were 66 
made according to the Kidney Disease Outcomes Quality Initiative (KDOQI) 67 
guidelines. Patients with a history and current treatment of diabetes mellitus, 68 
severe hypertension, urological disease of known etiology, glomerulonephritis, or 69 
snake bite were excluded. Creatinine concentration in urine sample was measured 70 
by enzyme assay using creatinine amidohydrolase (SRL, Tokyo, Japan). 71 
Urine samples were thawed and centrifuged at 15,000 rpm for 10 min to 72 
remove any cellular debris, and the supernatant was used for the determination of 73 
mycotoxin level. One milliliter of urine was diluted with 3 mL PBS (pH 7.4). The 74 
mixed sample was directly passed through analyte-specific immunoaffinity 75 
columns (R-Biopharm AG, Darmstadt, Germany) at a flow rate of 1–2 drops/s. 76 
The column was washed with 20 mL PBS and air was passed through the column 77 
for 1 min. The bound mycotoxin was eluted with 3 mL methanol and the eluate 78 
was evaporated to dryness using a nitrogen evaporator. The residue was 79 
reconstituted with 100 L 10% methanol in water, and analyzed for each 80 
mycotoxin with the specific competitive ELISA kits (RIDASCREEN FAST 81 
Mycotoxins; R-Biopharm AG) using a microplate spectrophotometer (infinite 82 
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M200 Pro; Tecan, Tokyo, Japan) at 450 nm. ELISA kits for AFL, OTs and FBs 83 
recognized aflatoxins B1, B2, G1, G2 and M1; ochratoxins A, B and C, and 84 
fumonisins B1, B2 and B3, respectively. External standards of different 85 
concentrations and all urine samples were run in duplicate.  86 
Mean recovery (CV) of fortified samples was 79% (11) for AFLs, 105% 87 
(13) for OTs and 92% (15) for FBs. Detection limits were 0.005 ng/mL, 0.005 88 
ng/mL and 0.035 ng/mL for AFLs, OTs and FBs, respectively. For values below 89 
the detection limit, half of the limit of detection value was assigned. Mycotoxin 90 
concentrations are presented in ng/mL and ng/g Cr (creatinine). Statistical 91 
significance of differences was tested by using non-parametric methods (χ2 test 92 
and Wilcoxon two-sample test; P < 0.05). 93 
 94 
Results and Discussion 95 
Study subjects comprised 20 men and 21 women (Table 1). The mean (range) age 96 
regardless of disease stage (31, stage 1–5) was 41.32 ± 15.55 (9–65) years, 97 
whereas that of unaffected relatives and Japanese controls was 20.67 (6–34) years 98 
and 45.25 (42–53) years, respectively.  99 
Results of urinary AFL, OT and FB levels are shown in Table 2. The 100 
percentage detection of AFLs, OTs and FBs in patients was 61.29%, 93.5% and 101 
19.4%, respectively. The detection rate of all mycotoxins in stage 1 disease was 102 
the highest. Disease stages were classified as early (stage 1 and 2) and late (stage 103 
3–5) for examination of concentration differences during disease progression. 104 
Detection rates of AFLs in the early and late stages were 78.57% and 47.06%, 105 
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respectively (χ2 = 9.323; P < 0.001). OTs were detected in all of the urine samples 106 
from 14 patients with early stage disease, whereas the rate of detection at the late 107 
stage was 88.24% (n = 17) (χ2 = 23.516, P < 0.001). Both AFLs and OTs were 108 
detected in all of the relatives of CKDue patients, but only OTs were detected in 109 
the Japanese controls. 110 
The highest AFL concentration in urine samples from CKDue patients was 111 
0.8 ng/mL,
 
whereas 90% of the samples had a concentration <0.044 ng/mL (397.1 112 
ng/g Cr). The 90th percentile for OTs was 0.098 ng/mL (60.85 ng/g Cr). The 113 
geometric means of urinary AFLs and OTs were 0.033 ng/mL
 
(30.93 ng/g Cr) and 114 
0.037 ng/mL (34.62 ng/g Cr) in the early stage, and 0.008 ng/mL
 
(10.40 ng/g Cr) 115 
and 0.012 ng/mL (17.08 ng/g Cr) in the late stage of the disease. Mean 116 
concentration difference for urinary OT level was observed between the early and 117 
late stages of the disease (Wilcoxon test, P = 0.008). In contrast, comparable 118 
concentrations of OTs and AFLs were also observed in the unaffected relatives of 119 
CKDue patients (P > 0.05 compared with all patients). Healthy Japanese 120 
individuals, however, had lower levels of OTs (0.007 ng/mL, 8.14 ng/g Cr) than 121 
Sri Lankan individuals had. 122 
The small sample size of the control subjects and their characteristic 123 
differences with the patients limit the comparability of the results. However, the 124 
high detection frequency and urinary levels of OTs and AFLs among CKDue 125 
patients and their relatives demonstrated the potential human exposure in the 126 
region. Findings were also discussed in relation to similar studies in other 127 
countries (Table 3). The average AFL concentration in urine samples from 128 
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CKDue patients was markedly higher, by over an order of magnitude, than the 129 
level of 0.391 ng/g Cr in the Czech Republic (Malir et al. 2004). An FB exposure 130 
study in two Portuguese populations has shown no detectable level in urine 131 
samples (Silva et al. 2008) and in Mexico 75% detection frequency was observed 132 
(Gong et al. 2008), whereas some level of FBs was detected at the early stage of 133 
the disease in the present study.  134 
Higher detection of OTs was observed compared with the 61% detection 135 
rate among healthy individuals in Hungary and 43% in the endemic nephropathy 136 
area in Croatia (Domijan et al. 2009), whereas the detection was comparable with 137 
the 88–97.8% in the endemic nephropathy region of Bulgaria (Castegnaro et al. 138 
2005). Although the mean OT level in CKDue patients in our study was higher 139 
than the 0.007 ng/mL in Croatia (Domijan et al. 2009) and 0.013 ng/mL in 140 
Hungary (Fazekas et al. 2004), and was comparable to the 0.022 ng/mL
 
in 141 
Portugal (Duarte et al. 2010), the urine concentration levels in half of our CKDue 142 
patients were <0.017 ng/mL (n = 15). The potential sources of exposure to OTs in 143 
the region need to be clarified.  144 
Animal studies have demonstrated the possibility of higher concentrations 145 
of OT A in kidney tissues and low levels in the urine (Zepnik et al. 2003). 146 
Likewise, an increase in OT A intake in humans in the region of endemic 147 
nephropathy did not result in an immediate increase in its elimination (Castegnaro 148 
et al. 2005). OT A is characterized by high plasma protein binding potential, 149 
therefore, its removal efficiency might be low (Petzinger et al. 2000; Ringot et al. 150 
2006), and it is possible that OT A accumulates in renal tissue. It is worth noting 151 
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that the cumulative effect of long-term consumption of products that contain low 152 
levels of mycotoxins could contribute to a gradual deterioration of organ function. 153 
This study is believed to be the first to determine the presence of AFLs, 154 
OTs and FBs in urine samples from CKDue patients and their relatives living in 155 
communities with CKDue. The higher detection rate of OTs in Sri Lanka has led 156 
to a working hypothesis that this mycotoxin could be common in the region, 157 
which corroborates the need for further exposure assessment, associated with 158 
disease occurrence. 159 
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Table 1. Baseline characteristics of CKDue patients in Sri Lanka, 2009 228 




Stage 1 (slight) 3/4 24.14 (9–40) 
Stage 2 (mild) 




36.07 ± 15.19‡ 
Stage 3 (moderate) 3/3 41 (11–60) 
Stage 4 (severe) 3/3 47.5 (35–58) 
Stage 5 (end stage) 3/2 49.00 (30–65) 
Stage 3–5 (late stage) 9/8 (17) 45.65 ± 14.90 
Total (CKDue 
patients) 
18/13 41.32 ± 15.55 (9–65) 
Relatives of CKDue 
patients  
2/4 20.67 (6–34) 









 AFL OT FB 
 ng/mL ng/g Cr ng/mL ng/g Cr ng/mL µg/g Cr 













 Mean 0.359 230.21 0.044 39.67 <MDL <MDL 
 GM 0.092 87.41 0.035 33.33 <MDL <MDL 













 Mean 0.018 19.58 0.085 65.07 - - 
 GM 0.012 10.95 0.039 35.95 - - 
Stage 1–2 GM 0.033 30.93 0.037 34.62* - - 









 Mean 0.023 25.57 0.022 21.76 - - 
 GM 0.022 18.75 0.016 19.36 - - 




ND–0.800 (4) ND–991.57 ND–0.019 (4) ND–34.27 - - 
 Mean 0.140 174.82 0.016 18.75 ND ND 
 GM 0.009 12.71 0.012 17.07 - - 




ND ND 0.010 (4) ND–27.06 ND ND 
 Mean - - 0.044 16.56 - - 
 GM - - 0.080 14.72 - - 
Stage 3–5 GM 0.008 10.40 0.012 17.08* - - 
Stage 1–5 GM 0.012 17.01 0.020 23.50 - - 
Relatives 













Mean 0.298 249.09 0.104 88.95 - - 
GM 0.112 84.12 0.085 63.52 - - 
Japanese 




ND ND 0.005–0.012 
(4) 
4.4–19.40 ND ND 
Mean - - 0.007 9.69 - - 
GM - - 0.007 8.14 - - 
ND: not detected; MDL: method detection limit; GM: geometric mean 233 












Mean (range)  Study subjects Country Reference 
 
AFL 61.29% 17.0 (ND–991.6) 
ng/gCr 
CKDue patients Sri Lanka Present study 
58% 391.0 (19.0–
19,219.0) pg/g Cr 
General population Czech 
Republic 
(Malir et al. 
2004) 




Sri Lanka Present study 
88.24% 12.0 (ND–58.2) 
pg/mL 
CKDue patients (late 
stage) 
Sri Lanka Present study 
100%(n=6) 85.0 (32.0–223.0) 
pg/mL 
Relatives of CKDue 
patients 
Sri Lanka Present study 
61% 13.0 (6.0–65.0) 
pg/mL 
Healthy individuals Hungary (Fazekas et al. 
2004) 
43% 7.0 (5.0–15.0) pg/mL Endemic nephropathy Croatia (Domijan et al. 
2009) 
92.20% 22.0 (ND–69.0) 
pg/mL  
General population Portugal (Duarte et al. 
2010) 
88% 50.8 (1.0–330.0) 
pg/mL 
Endemic nephropathy Bulgaria  (Castegnaro et 
al. 2005) 
97.6% 191.7 (1.0–191.0) 
pg/mL 
Endemic nephropathy Bulgaria (Castegnaro et 
al. 2005) 
FB 19.4% (ND–130.0 pg/mL) CKDue patients Sri Lanka Present study 
0% (LOD = 5 ng/mL) General population Portugal (Silva et al. 
2008) 
75% 70.1 (ND–9312.0) 
pg/mL  
General population Mexico (Gong et al. 
2008) 
 240 
 241 
